EarleyLE: Presentation of diagnostic criteria of the hepatorenal syndrome. In: Hepatorenal ascites formation in cirrhosis: role of atrial natriuretic factor. Syndrome, edited by BartoliE, ChiandussiL, Padova, Piccin Medical Books, 1979, pp 495–504
EarleyLE: Presentation of diagnostic criteria of the hepatorenal syndrome. In: Hepatorenal ascites formation in cirrhosis: role of atrial natriuretic factor. Syndrome, edited by BartoliE, ChiandussiL, Padova, Piccin Medical Books, 1979, pp 495–504)| false
ArroyoV, GinèsP, GerbesAL, DudleyFJ, GentiliniP, LaffiG, et al..: Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology23: 164–176, 1996PubMed
SalernoF, GerbesA, GinèsP, WongF, ArroyoV: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut56: 1310–1318, 2007PubMed
SalernoF, GerbesA, GinèsP, WongF, ArroyoV: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56: 1310–1318, 2007PubMed)| false
AngeliP, GinèsP, WongF, BernardiM, BoyerTD, GerbesA, et al..: Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol62: 968–974, 2015PubMed
AngeliP, GinèsP, WongF, BernardiM, BoyerTD, GerbesA, .: Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 62: 968–974, 2015PubMed10.1016/j.jhep.2014.12.029)| false
TrawaléJM, ParadisV, RautouPE, FrancozC, EscolanoS, SalléeM, et al..: The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int30: 725–732, 2010PubMed
TrawaléJM, ParadisV, RautouPE, FrancozC, EscolanoS, SalléeM, .: The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 30: 725–732, 2010PubMed10.1111/j.1478-3231.2009.02182.x)| false
MartinP-Y, GinèsP, SchrierRW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med339: 533–541, 1998PubMed
MartinP-Y, GinèsP, SchrierRW: Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 339: 533–541, 1998PubMed10.1056/NEJM199808203390807)| false
SolàE, GinèsP: Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol 53: 1135–1145, 2010PubMed10.1016/j.jhep.2010.08.001)| false
KastelanS, LjubicicN, KastelanZ, OstojicR, UravicM: The role of duplex-doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology51: 1408–1412, 2004PubMed
KastelanS, LjubicicN, KastelanZ, OstojicR, UravicM: The role of duplex-doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis. Hepatogastroenterology 51: 1408–1412, 2004PubMed)| false
KoppelMH, CoburnJW, MimsMM, GoldsteinH, BoyleJD, RubiniME: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med280: 1367–1371, 1969PubMed
KoppelMH, CoburnJW, MimsMM, GoldsteinH, BoyleJD, RubiniME: Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med 280: 1367–1371, 1969PubMed10.1056/NEJM196906192802501)| false
KalambokisGN, TsiakasI, ChristakiM, et al..: Systemic hemodynamic response to terlipressin predicts development of hepatorenal syndrome and survival in advanced cirrhosis. Eur J Gastroenterol Hepatol30: 659–667, 2018.
SalernoF, NavickisRJ, WilkesMM: Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol15: 167, 2015PubMed
SalernoF, NavickisRJ, WilkesMM: Albumin treatment regimen for type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC Gastroenterol 15: 167, 2015PubMed10.1186/s12876-015-0389-9)| false
KragA, BendtsenF, HenriksenJH, MøllerS: Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut59: 105–110, 2010PubMed
KragA, BendtsenF, HenriksenJH, MøllerS: Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59: 105–110, 2010PubMed10.1136/gut.2009.180570)| false
SerstéT, MelotC, FrancozC, DurandF, RautouPE, VallaD, et al..: Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology52: 1017–1022, 2010PubMed
SerstéT, MelotC, FrancozC, DurandF, RautouPE, VallaD, .: Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52: 1017–1022, 2010PubMed10.1002/hep.23775)| false
MandorferM, BotaS, SchwablP, BucsicsT, PfistererN, KruzikM, et al..: Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology146: 1680–90.e1, 2014PubMed
MandorferM, BotaS, SchwablP, BucsicsT, PfistererN, KruzikM, .: Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146: 1680–90.e1, 2014PubMed10.1053/j.gastro.2014.03.005)| false
AcevedoJ, FernándezJ, PradoV, SilvaA, CastroM, PavesiM, et al..: Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology58: 1757–1765, 2013PubMed
TheocharidouE, KragA, BendtsenF, MøllerS, BurroughsAK: Cardiac dysfunction in cirrhosis: does adrenal function play a role? A hypothesis. Liver Int32: 1327–1332, 2012PubMed
TheocharidouE, KragA, BendtsenF, MøllerS, BurroughsAK: Cardiac dysfunction in cirrhosis: does adrenal function play a role? A hypothesis. Liver Int 32: 1327–1332, 2012PubMed10.1111/j.1478-3231.2011.02751.x)| false
NavasaM, FolloA, FilellaX, JiménezW, FrancitorraA, PlanasR, et al..: Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology27: 1227–1232, 1998PubMed
NavasaM, FolloA, FilellaX, JiménezW, FrancitorraA, PlanasR, .: Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 27: 1227–1232, 1998PubMed10.1002/hep.510270507)| false
DavenportA, ArgawalB, WrightG, MantzoukisK, DimitrovaR, DavarJ, et al.: Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?World J Hepatol5: 433–438, 2013PubMed
DavenportA, ArgawalB, WrightG, MantzoukisK, DimitrovaR, DavarJ, : Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?World J Hepatol 5: 433–438, 2013PubMed10.4254/wjh.v5.i8.433)| false
UmgelterA, ReindlW, FranzenM, LenhardtC, HuberW, SchmidRM: Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med35: 152–156, 2009PubMed
UmgelterA, ReindlW, FranzenM, LenhardtC, HuberW, SchmidRM: Renal resistive index and renal function before and after paracentesis in patients with hepatorenal syndrome and tense ascites. Intensive Care Med 35: 152–156, 2009PubMed10.1007/s00134-008-1253-y)| false
SkrypnykNI, GistKM, OkamuraK, MontfordJR, YouZ, YangH, et al..: IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase-associated lipocalin during acute kidney injury. Kidney Int97: 966–979, 2020PubMed
SkrypnykNI, GistKM, OkamuraK, MontfordJR, YouZ, YangH, .: IL-6-mediated hepatocyte production is the primary source of plasma and urine neutrophil gelatinase-associated lipocalin during acute kidney injury. Kidney Int 97: 966–979, 2020PubMed10.1016/j.kint.2019.11.013)| false
SavinoJA, CerabonaT, AgarwalN, ByrneD: Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function. Ann Surg208: 504–511, 1988PubMed
SavinoJA, CerabonaT, AgarwalN, ByrneD: Manipulation of ascitic fluid pressure in cirrhotics to optimize hemodynamic and renal function. Ann Surg 208: 504–511, 1988PubMed10.1097/00000658-198810000-00012)| false
WongF, NadimMK, KellumJA, SalernoF, BellomoR, GerbesA, et al..: Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut60: 702–709, 2011PubMed
WongF, NadimMK, KellumJA, SalernoF, BellomoR, GerbesA, .: Working party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 60: 702–709, 2011PubMed10.1136/gut.2010.236133)| false
PianoS, RosiS, MaresioG, FasolatoS, CavallinM, RomanoA, et al..: Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol59: 482–489, 2013PubMed
WongF, PappasSC, CurryMP, ReddyKR, RubinRA, PoraykoMK, et al.; CONFIRM Study Investigators: Terlipressin plus albumin. N Engl J Med384: 818–828, 2021PubMed
DavenportA, CholongitasE, XirouchakisE, BurroughsAK: Pitfalls in assessing renal function in patients with cirrhosis: potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant26: 2735–2742, 2011PubMed
DavenportA, CholongitasE, XirouchakisE, BurroughsAK: Pitfalls in assessing renal function in patients with cirrhosis: potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 26: 2735–2742, 2011PubMed10.1093/ndt/gfr354)| false
SeoYS, ParkSY, KimMY, KimSG, ParkJY, YimHJ, et al..: Serum cystatin C level: an excellent predictor of mortality in patients with cirrhotic ascites. J Gastroenterol Hepatol33: 910–917, 2018PubMed
KronesE, FickertP, ZittaS, NeunherzS, ArtingerK, ReibneggerG, et al..: The chronic kidney disease epidemiology collaboration equation combining creatinine and cystatin C accurately assesses renal function in patients with cirrhosis. BMC Nephrol16: 196, 2015PubMed
AlsaadAA, WadeiHM: Fractional excretion of sodium in hepatorenal syndrome: clinical and pathological correlation. World J Hepatol8: 1497–1501, 2016PubMed
AlsaadAA, WadeiHM: Fractional excretion of sodium in hepatorenal syndrome: clinical and pathological correlation. World J Hepatol 8: 1497–1501, 2016PubMed10.4254/wjh.v8.i34.1497)| false
CarvounisCP, NisarS, Guro-RazumanS: Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int62: 2223–2229, 2002PubMed
CarvounisCP, NisarS, Guro-RazumanS: Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 62: 2223–2229, 2002PubMed10.1046/j.1523-1755.2002.00683.x)| false
PatidarKR, KangL, BajajJS, CarlD, SanyalAJ: Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology68: 224–233, 2018PubMed
PatidarKR, KangL, BajajJS, CarlD, SanyalAJ: Fractional excretion of urea: a simple tool for the differential diagnosis of acute kidney injury in cirrhosis. Hepatology 68: 224–233, 2018PubMed10.1002/hep.29772)| false
BelcherJM, SanyalAJ, Garcia-TsaoG, AnsariN, CocaSG, ShlipakMG, et al..: Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol2014: 708585, 2014PubMed
BelcherJM, SanyalAJ, Garcia-TsaoG, AnsariN, CocaSG, ShlipakMG, .: Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol 2014: 708585, 2014PubMed10.1155/2014/708585)| false
ArizaX, SolàE, EliaC, BarretoR, MoreiraR, Morales-RuizM, et al..: Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One10: e0128145, 2015PubMed
ArizaX, SolàE, EliaC, BarretoR, MoreiraR, Morales-RuizM, .: Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One 10: e0128145, 2015PubMed10.1371/journal.pone.0128145)| false
WatanyMM, HagagRY, OkdaHI: Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. Clin Chem Lab Med56: 739–747, 2018PubMed
WatanyMM, HagagRY, OkdaHI: Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. Clin Chem Lab Med 56: 739–747, 2018PubMed10.1515/cclm-2017-0483)| false
HuelinP, SolàE, EliaC, SoléC, RissoA, MoreiraR, et al..: Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology70: 319–333, 2019PubMed
HuelinP, SolàE, EliaC, SoléC, RissoA, MoreiraR, .: Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology 70: 319–333, 2019PubMed)| false
ArroyoV, JiménezW: Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol32[Suppl]: 157–170, 2000PubMed
ArroyoV, JiménezW: Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 32[Suppl]: 157–170, 2000PubMed10.1016/S0168-8278(00)80423-7)| false
SortP, NavasaM, ArroyoV, AldeguerX, PlanasR, Ruiz-del-ArbolL, et al..: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med341: 403–409, 1999PubMed
SortP, NavasaM, ArroyoV, AldeguerX, PlanasR, Ruiz-del-ArbolL, .: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 341: 403–409, 1999PubMed10.1056/NEJM199908053410603)| false
ChinaL, FreemantleN, ForrestE, KallisY, RyderSD, WrightG, et al.; ATTIRE Trial Investigators: A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med384: 808–817, 2021PubMed
ChinaL, FreemantleN, ForrestE, KallisY, RyderSD, WrightG, ; ATTIRE Trial Investigators: A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 384: 808–817, 2021PubMed10.1056/NEJMoa2022166)| false
CadeR, WagemakerH, VogelS, MarsD, Hood-LewisD, PrivetteM, et al..: Hepatorenal syndrome: studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med82: 427–438, 1987PubMed
CadeR, WagemakerH, VogelS, MarsD, Hood-LewisD, PrivetteM, .: Hepatorenal syndrome: studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function. Am J Med 82: 427–438, 1987PubMed10.1016/0002-9343(87)90442-6)| false
KangDJ, KakiyamaG, BetrapallyNS, HerzogJ, NittonoH, HylemonPB, et al..: Rifaximin exerts beneficial effects independent of its ability to alter microbiota composition. Clin Transl Gastroenterol7: e187, 2016PubMed
CaraceniP, VargasV, SolàE, AlessandriaC, de WitK, TrebickaJ, et al.; Liverhope Consortium: The use of rifaximin in patients with cirrhosis. Hepatology74: 1660–1673, 202110.1002/hep.31708PubMed
CaraceniP, VargasV, SolàE, AlessandriaC, de WitK, TrebickaJ, ; Liverhope Consortium: The use of rifaximin in patients with cirrhosis. Hepatology 74: 1660–1673, 202110.1002/hep.31708PubMed10.1002/hep.31708)| false
SanyalAJ, BoyerTD, FrederickRT, WongF, RossaroL, ArayaV, et al..: Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther45: 1390–1402, 2017PubMed
SanyalAJ, BoyerTD, FrederickRT, WongF, RossaroL, ArayaV, .: Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther 45: 1390–1402, 2017PubMed10.1111/apt.14052)| false
AdebayoD, MorabitoV, DavenportA, JalanR: Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 87: 509–515, 2015PubMed10.1038/ki.2014.338)| false
NadimMK, DurandF, KellumJA, LevitskyJ, O’LearyJG, KarvellasCJ, et al..: Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol64: 717–735, 2016PubMed
European Association for the Study of Liver Diseases: EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol33: 591–598, 2018
European Association for the Study of Liver Diseases: EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 33: 591–598, 2018)| false
JamilK, PappasSC, DevarakondaKR: In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2. J Exp Pharmacol10: 1–7, 2017PubMed
JamilK, PappasSC, DevarakondaKR: In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2. J Exp Pharmacol 10: 1–7, 2017PubMed10.2147/JEP.S146034)| false
FabriziF, AghemoA, MessaP: Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res 37: 588–601, 2013PubMed10.1159/000355739)| false
Nassar JuniorAP, FariasAQ, D’ AlbuquerqueLA, CarrilhoFJ, MalbouissonLM: Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One9: e107466, 2014PubMed
Nassar JuniorAP, FariasAQ, D’ AlbuquerqueLA, CarrilhoFJ, MalbouissonLM: Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One 9: e107466, 2014PubMed10.1371/journal.pone.0107466)| false
MattosAZ, MattosAA, RibeiroRA: Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol28: 345–351, 2016PubMed
MattosAZ, MattosAA, RibeiroRA: Terlipressin versus noradrenaline in the treatment of hepatorenal syndrome: systematic review with meta-analysis and full economic evaluation. Eur J Gastroenterol Hepatol 28: 345–351, 2016PubMed10.1097/MEG.0000000000000537)| false
WongF, PanteaL, SnidermanK: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology40: 55–64, 2004PubMed
WongF, PanteaL, SnidermanK: Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40: 55–64, 2004PubMed10.1002/hep.20262)| false
CavallinM, KamathPS, MerliM, FasolatoS, ToniuttoP, SalernoF, et al.; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome: Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology62: 567–574, 2015PubMed
CavallinM, KamathPS, MerliM, FasolatoS, ToniuttoP, SalernoF, ; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome: Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology 62: 567–574, 2015PubMed10.1002/hep.27709)| false
BestLM, FreemanSC, SuttonAJ, CooperNJ, TngEL, CsenarM, et al..: Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev9: CD013103, 2019PubMed
BestLM, FreemanSC, SuttonAJ, CooperNJ, TngEL, CsenarM, .: Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 9: CD013103, 2019PubMed)| false
ReibergerT: When should we stop treatment with terlipressin and albumin for patients with hepatorenal syndrome?Clin Gastroenterol Hepatol16: 1710–1711, 2018PubMed
ReibergerT: When should we stop treatment with terlipressin and albumin for patients with hepatorenal syndrome?Clin Gastroenterol Hepatol 16: 1710–1711, 2018PubMed10.1016/j.cgh.2018.04.020)| false
FacciorussoA, ChandarAK, MuradMH, ProkopLJ, MuscatielloN, KamathPS, et al..: Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol2: 94–102, 2017PubMed
AroraV, MaiwallR, RajanV, JindalA, Muralikrishna ShasthryS, KumarG, et al..: Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology71: 600–610, 2020PubMed
AroraV, MaiwallR, RajanV, JindalA, Muralikrishna ShasthryS, KumarG, .: Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology 71: 600–610, 2020PubMed10.1002/hep.30208)| false
BoyerTD, SanyalAJ, Garcia-TsaoG, BleiA, CarlD, BexonAS, et al.; Terlipressin Study Group: Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol55: 315–321, 2011PubMed
BoyerTD, SanyalAJ, Garcia-TsaoG, BleiA, CarlD, BexonAS, ; Terlipressin Study Group: Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 55: 315–321, 2011PubMed10.1016/j.jhep.2010.11.020)| false
SnowdonVK, LachlanNJ, HoyAM, HadokePW, SempleSI, PatelD, et al..: Serelaxin as a potential treatment for renal dysfunction in cirrhosis: preclinical evaluation and results of a randomized phase 2 trial. PLoS Med14: e1002248, 2017PubMed
SnowdonVK, LachlanNJ, HoyAM, HadokePW, SempleSI, PatelD, .: Serelaxin as a potential treatment for renal dysfunction in cirrhosis: preclinical evaluation and results of a randomized phase 2 trial. PLoS Med 14: e1002248, 2017PubMed10.1371/journal.pmed.1002248)| false
ZhangZ, MaddukuriG, JaipaulN, CaiCX: Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care30: 969–974, 2015PubMed
ZhangZ, MaddukuriG, JaipaulN, CaiCX: Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care 30: 969–974, 2015PubMed10.1016/j.jcrc.2015.05.006)| false
WongF, RainaN, RichardsonR: Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut59: 381–386, 2010PubMed
WongF, RainaN, RichardsonR: Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 59: 381–386, 2010PubMed10.1136/gut.2008.174615)| false
ValerioC, TheocharidouE, DavenportA, AgarwalB: Human albumin solution for patients with cirrhosis and acute on chronic liver failure: beyond simple volume expansion. World J Hepatol8: 345–354, 2016PubMed
ValerioC, TheocharidouE, DavenportA, AgarwalB: Human albumin solution for patients with cirrhosis and acute on chronic liver failure: beyond simple volume expansion. World J Hepatol 8: 345–354, 2016PubMed10.4254/wjh.v8.i7.345)| false
